The efficiency and safety of tocilizumab in rheumatoid arthritis(intermediate results of a Russian multicenter study)
A search for new medicines for the treatment of rheumatoid arthritis (RA) has led to the design of the so-called genetic engineering biologicals (GEBs) whose mechanism of action lies in the depletion and impaired interaction of the cells involved in the development of i НАУЧНО-ПРАКТИЧЕСКАЯ РЕВМАТОЛО...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2010-04-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/1251 |
| _version_ | 1797862827459870720 |
|---|---|
| author | E L Nasonov Elena Yuryevna Panasyuk S G Buldakov A B Pavlova L A Knyazeva R G Kamalova I B Vinogradova E A Shikina T A Raskina A A Dmitriyeva R S Saikovsky A V Elonakov V N Amirdzhanova E N Aleksandrova |
| author_facet | E L Nasonov Elena Yuryevna Panasyuk S G Buldakov A B Pavlova L A Knyazeva R G Kamalova I B Vinogradova E A Shikina T A Raskina A A Dmitriyeva R S Saikovsky A V Elonakov V N Amirdzhanova E N Aleksandrova |
| author_sort | E L Nasonov |
| collection | DOAJ |
| description | A search for new medicines for the treatment of rheumatoid arthritis (RA) has led to the design of the so-called genetic engineering biologicals (GEBs) whose mechanism of action lies in the depletion and impaired interaction of the cells involved in the development of i НАУЧНО-ПРАКТИЧЕСКАЯ РЕВМАТОЛОГИЯ, 2010, № 2, 21-29 21 ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ nflammation or in the inhibition of proinflammatory cytokine activities. In recent years, investigators' attention has been brought to interleukin (IL) 6 (pleiotropic cytokine) that is synthesized by many cells implicated in the development of inflammation and shows a broad range of proinflammatory biological effects. Tocilizumab (TCZ) is the first and only agent that is able to suppress IL-6-dependent inflammatory reactions and that is permitted for use in RA. The first Russian open-label, Phase IV, multicenter 24-week study of the efficacy and safety of TCZ in patients with rheumatoid arthritis (RA) is now under way. All the patients received an intravenous TCZ infusion in a dose of 8 mg/kg during continuous therapy with basic anti-inflammatory and nonsteroidal anti-inflammatory drugs (DMARDs and NSAIDs), and glucocorticoids. The patients receiving methotrexate (MT) took folic acid in a dose of at least 5 mg weekly. The study excluded patients with a history of DMARD use. To evaluate the efficiency of TCZ therapy, the authors used the EULAR criteria and analyzed individual clinical indicators of RA activity, including the intensity of pain, the duration of morning stiffness, the number of tender and swollen joints (TJC and SJC), indices of functional activity and quality of life (HAQ and EQ-5D), and laboratory parameters required to evaluate the efficiency and safety of TCZ therapy. Clinical and laboratory studies were conducted just before and 4 weeks after the first infusion of TCZ. Overall, the first administration of the drug caused a very rapid positive effect against all clinical indicators of disease activity (including pain magnitude, morning stiffness duration, TJC, SJC) and normalization of the indices characterizing the functional activity and quality of life of patients. The efficiency TCZ therapy was confirmed, by assessing the time course of changes in DAS 28 index values: before therapy, all the patients were observed to have a high activity of RA (DAS 28 >5,1). According to the changes in DAS 28 index values, a good/moderate effect was noted in 62% of the patients, 3 (7%) achieved remission (DAS 28 |
| first_indexed | 2024-04-09T22:26:54Z |
| format | Article |
| id | doaj.art-0c498654c1c94efbbcb02375eca054a1 |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2024-04-09T22:26:54Z |
| publishDate | 2010-04-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-0c498654c1c94efbbcb02375eca054a12023-03-22T13:45:45ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922010-04-01482212910.14412/1995-4484-2010-14121191The efficiency and safety of tocilizumab in rheumatoid arthritis(intermediate results of a Russian multicenter study)E L NasonovElena Yuryevna PanasyukS G BuldakovA B PavlovaL A KnyazevaR G KamalovaI B VinogradovaE A ShikinaT A RaskinaA A DmitriyevaR S SaikovskyA V ElonakovV N AmirdzhanovaE N AleksandrovaA search for new medicines for the treatment of rheumatoid arthritis (RA) has led to the design of the so-called genetic engineering biologicals (GEBs) whose mechanism of action lies in the depletion and impaired interaction of the cells involved in the development of i НАУЧНО-ПРАКТИЧЕСКАЯ РЕВМАТОЛОГИЯ, 2010, № 2, 21-29 21 ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ nflammation or in the inhibition of proinflammatory cytokine activities. In recent years, investigators' attention has been brought to interleukin (IL) 6 (pleiotropic cytokine) that is synthesized by many cells implicated in the development of inflammation and shows a broad range of proinflammatory biological effects. Tocilizumab (TCZ) is the first and only agent that is able to suppress IL-6-dependent inflammatory reactions and that is permitted for use in RA. The first Russian open-label, Phase IV, multicenter 24-week study of the efficacy and safety of TCZ in patients with rheumatoid arthritis (RA) is now under way. All the patients received an intravenous TCZ infusion in a dose of 8 mg/kg during continuous therapy with basic anti-inflammatory and nonsteroidal anti-inflammatory drugs (DMARDs and NSAIDs), and glucocorticoids. The patients receiving methotrexate (MT) took folic acid in a dose of at least 5 mg weekly. The study excluded patients with a history of DMARD use. To evaluate the efficiency of TCZ therapy, the authors used the EULAR criteria and analyzed individual clinical indicators of RA activity, including the intensity of pain, the duration of morning stiffness, the number of tender and swollen joints (TJC and SJC), indices of functional activity and quality of life (HAQ and EQ-5D), and laboratory parameters required to evaluate the efficiency and safety of TCZ therapy. Clinical and laboratory studies were conducted just before and 4 weeks after the first infusion of TCZ. Overall, the first administration of the drug caused a very rapid positive effect against all clinical indicators of disease activity (including pain magnitude, morning stiffness duration, TJC, SJC) and normalization of the indices characterizing the functional activity and quality of life of patients. The efficiency TCZ therapy was confirmed, by assessing the time course of changes in DAS 28 index values: before therapy, all the patients were observed to have a high activity of RA (DAS 28 >5,1). According to the changes in DAS 28 index values, a good/moderate effect was noted in 62% of the patients, 3 (7%) achieved remission (DAS 28https://rsp.mediar-press.net/rsp/article/view/1251tocilizumabrheumatoid arthritisfunctional activityquality of life |
| spellingShingle | E L Nasonov Elena Yuryevna Panasyuk S G Buldakov A B Pavlova L A Knyazeva R G Kamalova I B Vinogradova E A Shikina T A Raskina A A Dmitriyeva R S Saikovsky A V Elonakov V N Amirdzhanova E N Aleksandrova The efficiency and safety of tocilizumab in rheumatoid arthritis(intermediate results of a Russian multicenter study) Научно-практическая ревматология tocilizumab rheumatoid arthritis functional activity quality of life |
| title | The efficiency and safety of tocilizumab in rheumatoid arthritis(intermediate results of a Russian multicenter study) |
| title_full | The efficiency and safety of tocilizumab in rheumatoid arthritis(intermediate results of a Russian multicenter study) |
| title_fullStr | The efficiency and safety of tocilizumab in rheumatoid arthritis(intermediate results of a Russian multicenter study) |
| title_full_unstemmed | The efficiency and safety of tocilizumab in rheumatoid arthritis(intermediate results of a Russian multicenter study) |
| title_short | The efficiency and safety of tocilizumab in rheumatoid arthritis(intermediate results of a Russian multicenter study) |
| title_sort | efficiency and safety of tocilizumab in rheumatoid arthritis intermediate results of a russian multicenter study |
| topic | tocilizumab rheumatoid arthritis functional activity quality of life |
| url | https://rsp.mediar-press.net/rsp/article/view/1251 |
| work_keys_str_mv | AT elnasonov theefficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT elenayuryevnapanasyuk theefficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT sgbuldakov theefficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT abpavlova theefficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT laknyazeva theefficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT rgkamalova theefficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT ibvinogradova theefficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT eashikina theefficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT taraskina theefficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT aadmitriyeva theefficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT rssaikovsky theefficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT avelonakov theefficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT vnamirdzhanova theefficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT enaleksandrova theefficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT elnasonov efficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT elenayuryevnapanasyuk efficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT sgbuldakov efficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT abpavlova efficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT laknyazeva efficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT rgkamalova efficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT ibvinogradova efficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT eashikina efficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT taraskina efficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT aadmitriyeva efficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT rssaikovsky efficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT avelonakov efficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT vnamirdzhanova efficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy AT enaleksandrova efficiencyandsafetyoftocilizumabinrheumatoidarthritisintermediateresultsofarussianmulticenterstudy |